Plozalizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CCR2 |
Clinical data | |
Other names | hu1D9 |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6490H10052N1736O2018S42 |
Molar mass | 146032.46 g·mol−1 |
Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]
This drug was developed by Takeda Pharmaceuticals International Co.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Plozalizumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).